• Users Online: 295
  • Home
  • Print this page
  • Email this page
Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Contacts Login 
REVIEW ARTICLE
Year : 2020  |  Volume : 33  |  Issue : 4  |  Page : 213-221

Convalescent plasma therapy for Covid-19: A systematic review


1 Department of Clinical Haematology, All India Institute of Medical Sciences, Ansari Nagar, New Delhi 110029, India
2 Department of Neurology, All India Institute of Medical Sciences, Ansari Nagar, New Delhi 110029, India
3 Department of Medical Oncology, All India Institute of Medical Sciences, Ansari Nagar, New Delhi 110029, India
4 Department of Gastroenterology and Human Nutrition Unit, All India Institute of Medical Sciences, Ansari Nagar, New Delhi 110029, India
5 Department of Pulmonary Medicine, Critical Care and Sleep Disorders, All India Institute of Medical Sciences, Ansari Nagar, New Delhi 110029, India
6 Department of Medicine, All India Institute of Medical Sciences, Ansari Nagar, New Delhi 110029, India

Correspondence Address:
Atul Sharma
Department of Medical Oncology, All India Institute of Medical Sciences, Ansari Nagar, New Delhi 110029
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/0970-258X.296202

Background. Covid-19 has emerged as a pandemic affecting more than 20 million people till date with few, if any, proven therapy. Convalescent plasma (CP) containing antibodies against the virus has been used with some success. We did a systematic review to synthesize the available data on CP therapy for treatment of Covid-19 to study the efficacy and safety outcomes. Methods. Two reviewers searched the published and pre-published literature between 1 January 2019 and 23 June 2020 for studies comparing the use of CP with standard therapy for Covid-19 patients. Data from the selected studies were abstracted and analysed for efficacy and safety outcomes. Critical appraisal of the evidence was done by using the Joanna Briggs Institute tool and the quality of evidence was graded as per GRADE. Results. We found 13 case series and 1 randomized trial that fulfilled our search criteria. Of the 12 case series with a total of 264 patients that reported the efficacy outcomes, 11 studies showed favourable results with survival benefit. The only RCT with 103 patients did not show any mortality benefit but was terminated early prior to complete enrolment. A single large study of 5000 patients reported safety outcomes and showed no major adverse events in patient streated with CP. Conclusion. There is very low-quality evidence to suggest efficacy and safety of CP in patients with Covid-19 infection. Well-designed randomized trials are urgently needed to provide robust data.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed1919    
    Printed91    
    Emailed0    
    PDF Downloaded208    
    Comments [Add]    
    Cited by others 1    

Recommend this journal